

MILESTONES AHEAD

How early integration
eliminates enterprise rework

Most biotech companies don't struggle with execution. They struggle with **the alignment that maximizes value.** Across portfolios, regions, and stakeholders, **small disconnects** can quickly become **costly rework.**



THE JOURNEY

Complexity compounds

Biotech enterprise programs often face:

Fragmented data
and evidence
strategies

Inconsistent
patient
engagement

Regional
misalignments

Evidence gaps
for regulators,
HTAs and payers



THE REWORK ZONE

The cost of silos

Without early integration, biotech teams risk:

- **Delays** across programs
- **Duplicative** studies and evidence generation
- **Inconsistent** market evidence packages
- **Slower** access and payer decisions
- **Rework** across clinical, regulatory, commercial and manufacturing teams

The biggest **ROADBLOCK**
is **INTEGRATION**



THE SMARTER ROUTE

One strategy, globally operationalized

An integrated model connects:

Portfolio-level
value and
evidence
planning

Patient
recruitment
and
engagement

AI-enabled
insights and
workflows

CDMO
planning for
speed and
scale

Clinical,
commercial
and RWE
frameworks

Deep
therapeutic
expertise

Global
endpoints,
messaging and
access strategy



BUILT FOR SPEED AND SCALE

Integration strengthens the drivers that matter most:




Patients:
Better access,
enrollment,
retention and
experience



Data, AI and RWE:
Faster insights,
smarter trial design,
stronger evidence



**Medical and market
access:** Aligned value
stories across
stakeholders and regions



**Therapeutic and CDMO
expertise:** Smoother
transitions from development
to manufacturing to clinic



PORTFOLIO IMPACT

Same portfolio. Greater value.

WITHOUT INTEGRATION

- Asset-by-asset planning
- Regional inconsistency
- Delayed enrollment
- Fragmented evidence

VS

WITH INTEGRATION

- Portfolio-wide strategy
- Harmonized execution
- Optimized patient journey
- Consistent global value story



THE DESTINATION

Are your **programs optimizing** or just advancing?
Avoid the biggest pothole: **backtracking** because of
short-sighted planning.

Discover how we **enable enterprise-wide execution.**

LEARN MORE

ppd.com/our-solutions/biotech-solutions/

© 2026 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. 06.2026